Pentacarinat and Anaphylaxis - a phase IV clinical study of FDA data

Summary:

Anaphylaxis is reported as a side effect among people who take Pentacarinat (pentamidine isethionate), especially for people who are female, 60+ old, also take Darzalex, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Anaphylaxis when taking Pentacarinat. It is created by eHealthMe based on reports of 1,546 people who have side effects when taking Pentacarinat from the FDA, and is updated regularly.

What is Pentacarinat?

Pentacarinat has active ingredients of pentamidine isethionate. eHealthMe is studying from 1,546 Pentacarinat users. Check the latest studies of Pentacarinat.

What is Anaphylaxis?

Anaphylaxis (serious allergic reaction that is rapid in onset and may cause death) is found to be associated with 1,929 drugs and 2,859 conditions by eHealthMe. Check the latest studies of Anaphylaxis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

1,546 people reported to have side effects when taking Pentacarinat.
Among them, 16 people (1.03%) have Anaphylaxis.

Among these 16 people:

What is the gender of people who have Anaphylaxis when taking Pentacarinat? *

female: 66.67 %
male: 33.33 %

What is the age of people who have Anaphylaxis when taking Pentacarinat? *

What are other drugs people take besides Pentacarinat? *

What are other side effects people have besides Anaphylaxis? *

Bradycardia (abnormally slow heart action): 7 people, 43.75%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 7 people, 43.75%
Multiple Myeloma (cancer of the plasma cells): 7 people, 43.75%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 7 people, 43.75%
Acute Respiratory Failure: 7 people, 43.75%
Fever: 4 people, 25.00%
Erythema Multiforme (a type of hypersensitivity reaction): 4 people, 25.00%
Blood Bilirubin Increased: 3 people, 18.75%
Cholestasis (a condition where bile cannot flow from the liver to the duodenum): 3 people, 18.75%
Confusional State: 3 people, 18.75%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 7 people, 43.75%
Pain: 1 person, 6.25%
Osteosarcoma (a cancerous (malignant) bone tumour): 1 person, 6.25%
Fungal Infection: 1 person, 6.25%
Cytomegalovirus Gastrointestinal Infection (virus infection of stomach and intestine): 1 person, 6.25%
Constipation: 1 person, 6.25%
Acute Lymphocytic Leukaemia Recurrent (cancer in which the bone marrow makes too many lymphocytes-recurrent): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Pentacarinat and have Anaphylaxis?

- Check whether Anaphylaxis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Pentacarinat:

Pentacarinat (1,546 reports)

Anaphylaxis treatments and more:

Anaphylaxis (91,195 reports)

Browse all side effects of Pentacarinat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Anaphylaxis:

Anaphylaxis (1,929 drugs)

Browse all the conditions that are associated with Anaphylaxis:

Anaphylaxis (2,859 conditions)

Related publications that referenced our studies

An?eli? N, Erdeljan S, Popovi? R, Bo?i? T, "Anaphylaxis on graft reperfusion during orthotopic liver transplantation: A case study", Srpski arhiv za celokupno lekarstvo, 2016 Jan .
Thangakunam B, Christopher DJ, Mathews V, Srivastava A, "Mesenchymal stromal stem cell therapy in advanced interstitial lung disease-Anaphylaxis and short-term follow-up", Lung India: official organ of Indian Chest Society, 2015 Jan .
Guensley Delva, M. D., & Muse, I, "Rare case of laryngeal edema and anaphylaxis to Ofirmev (IV Acetaminophen): Case Report", , 2012 Jan .
Azkur D, Yoldas T, Toyran M, Kocabas CN, "A pediatric case of anaphylaxis due to octreotide", Asian Pacific journal of allergy and immunology, 2011 Dec .
An?eli? N, Erdeljan S, Popovi? R, Bo?i? T, "Anaphylaxis on graft reperfusion during orthotopic liver transplantation: A case study", Srpski arhiv za celokupno lekarstvo, 2016 Jan .
Thangakunam B, Christopher DJ, Mathews V, Srivastava A, "Mesenchymal stromal stem cell therapy in advanced interstitial lung disease-Anaphylaxis and short-term follow-up", Lung India: official organ of Indian Chest Society, 2015 Jan .
Guensley Delva, M. D., & Muse, I, "Rare case of laryngeal edema and anaphylaxis to Ofirmev (IV Acetaminophen): Case Report", , 2012 Jan .
Azkur D, Yoldas T, Toyran M, Kocabas CN, "A pediatric case of anaphylaxis due to octreotide", Asian Pacific journal of allergy and immunology, 2011 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on pentamidine isethionate (the active ingredients of Pentacarinat) and Pentacarinat (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.